Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of KN052 in Chinese Subjects With Advanced Solid Tumors
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Terminated
Based on the differentiated R\&D strategy, the sponsor applies for the termination of the project.
Other terminated trials from Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Advanced Solid Tumor · Phase PHASE1/PHASE2 · Jul 2025
- Colorectal Cancer with Hepatic Metastases · Phase PHASE2 · Jan 2025
- Thymic Carcinoma · Phase PHASE2 · Jul 2023
- Thymic Carcinoma · Phase PHASE2 · May 2023
- Advanced Non-small Cell Lung Cancer · Phase PHASE2/PHASE3 · Apr 2023
More terminations from Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Other Advanced Solid Tumor trials with similar outcome
A PHASE1 clinical study on Advanced Solid Tumor, this trial is terminated or withdrawn. The trial is conducted by Jiangsu Alphamab Biopharmaceuticals Co., Ltd and has accumulated 6 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Oct 2023 — Jun 2024 [monthly]
Recruiting PHASE1
-
Jul 2022 — Oct 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
May 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .